Tissue plasminogen activator (tPA) may be considered in pregnancy in which circumstances?

Tissue plasminogen activator (tPA) may be considered in pregnancy in which circumstances?

• A. Life-threatening PE or stroke
• B. Routine DVT prophylaxis
• C. Mild preeclampsia
• D. Normal postpartum period

Answer: (A)

The situation where tissue plasminogen activator is considered in pregnancy is a life‑saving, emergency use to rapidly dissolve a dangerous clot. Thrombolysis can be lifesaving for a massive pulmonary embolism or a large acute ischemic stroke when the mother’s condition is unstable and the benefits outweigh the risk of serious bleeding. In these dire cases, the goal is to restore perfusion quickly to prevent collapse or irreversible brain injury, even though this treatment carries bleeding risks for both mother and fetus. Routine DVT prophylaxis is not treated with tPA; it relies on anticoagulants like heparin or LMWH to prevent clot formation rather than dissolve existing clots. Mild preeclampsia is managed with blood pressure control, seizure prophylaxis, and delivery planning rather than clot-busting therapy. A normal postpartum period is not an indication for thrombolysis, since there’s no emergent clotting event to address. So, the best fit is using tPA only in a life-threatening thrombotic emergency, where rapid clot dissolution could save the mother’s life and the clinical team has weighed the bleeding risks against the potential benefit.

The situation where tissue plasminogen activator is considered in pregnancy is a life‑saving, emergency use to rapidly dissolve a dangerous clot. Thrombolysis can be lifesaving for a massive pulmonary embolism or a large acute ischemic stroke when the mother’s condition is unstable and the benefits outweigh the risk of serious bleeding. In these dire cases, the goal is to restore perfusion quickly to prevent collapse or irreversible brain injury, even though this treatment carries bleeding risks for both mother and fetus.

Routine DVT prophylaxis is not treated with tPA; it relies on anticoagulants like heparin or LMWH to prevent clot formation rather than dissolve existing clots. Mild preeclampsia is managed with blood pressure control, seizure prophylaxis, and delivery planning rather than clot-busting therapy. A normal postpartum period is not an indication for thrombolysis, since there’s no emergent clotting event to address.

So, the best fit is using tPA only in a life-threatening thrombotic emergency, where rapid clot dissolution could save the mother’s life and the clinical team has weighed the bleeding risks against the potential benefit.